[Decreases in plasma antithrombin III, fibrinogen, factor IX, X and XI, fibronectin and thyroxine binding globulin during therapy with L-asparaginase, vincristine and prednisolone in a patient with CML blastic crisis].
D000925:Anticoagulants / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000990:Antithrombin III / Q000032:analysis; D001215:Asparaginase / Q000008:administration & dosage; D005164:Factor IX / Q000032:analysis; D005170:Factor X / Q000032:analysis; D005172:Factor XI / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005353:Fibronectins / Q000032:analysis; D006801:Humans; D007951:Leukemia, Myeloid / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D013975:Thyroxine-Binding Proteins / Q000032:analysis*; D014750:Vincristine / Q000008:administration & dosage
D000925:Anticoagulants; D005353:Fibronectins; D013975:Thyroxine-Binding Proteins; D014750:Vincristine; D000990:Antithrombin III; D005164:Factor IX; D005170:Factor X; D005340:Fibrinogen; D005172:Factor XI; D011239:Prednisolone; D001215:Asparaginase